{"id":"NCT01327885","sponsor":"Eisai Inc.","briefTitle":"Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma","officialTitle":"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-10","primaryCompletion":"2015-01-02","completion":"2016-08-10","firstPosted":"2011-04-04","resultsPosted":"2017-02-28","lastUpdate":"2023-06-22"},"enrollment":452,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Soft Tissue Sarcoma"],"interventions":[{"type":"DRUG","name":"Eribulin mesylate 1.4 mg/m^2 intravenous","otherNames":[]},{"type":"DRUG","name":"Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV","otherNames":[]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin with dacarbazine in subjects with advanced soft tissue sarcoma who have disease progression within 6 months prior to study enrolment following standard therapies which must have included an anthracycline, unless contraindicated and then at least one additional regimen after failure of the anthracycline.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From date of treatment start until date of death from any cause, up to 5 years 5 months","effectByArm":[{"arm":"Arm A: Eribulin Mesylate","deltaMin":13.5,"sd":null},{"arm":"Arm B: Dacarbazine","deltaMin":11.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0169"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":119,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","France","Germany","Israel","Italy","Netherlands","New Zealand","Poland","Romania","Russia","Singapore","South Korea","Spain","Thailand","United Kingdom"]},"refs":{"pmids":["26874885"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":76,"n":228},"commonTop":["Nausea","Fatigue","Neutropenia","Anaemia","Constipation"]}}